(Q38995083)

8 September 2017

title

Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate (English)

1 reference

8 September 2017

0 references

0 references

1 reference

5

1 reference

8 September 2017

Peter Gottfried Kremsner

2

object named as

Peter G Kremsner

1 reference

8 September 2017

13

Benjamin Mordmüller

1 reference

8 September 2017

Meral Esen

1

1 reference

8 September 2017

Regina Schleucher

3

1 reference

8 September 2017

Michael Gässler

4

1 reference

8 September 2017

Nathalie Imbault

6

1 reference

8 September 2017

Odile Leroy

7

1 reference

8 September 2017

Søren Jepsen

8

1 reference

8 September 2017

Birgitte Walther Knudsen

9

1 reference

8 September 2017

Michael Schumm

10

1 reference

8 September 2017

Jürgen Knobloch

11

1 reference

8 September 2017

Michael Theisen

12

1 reference

8 September 2017

language of work or name

English

0 references

publication date

13 September 2009

1 reference

8 September 2017

1 reference

8 September 2017

volume

27

1 reference

8 September 2017

issue

49

1 reference

8 September 2017

page(s)

6862-6868

1 reference

THE IMMUNIZATION OF FOWLS AGAINST MOSQUITO-BORNE PLASMODIUM GALLINACEUM BY INJECTIONS OF SERUM AND OF INACTIVATED HOMOLOGOUS SPOROZOITES

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Gamma-globulin and acquired immunity to human malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich pro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Antibody-dependent ingestion of P. falciparum merozoites by human blood monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Humoral responses to plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Maintenance of serological memory by polyclonal activation of human memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Recent advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Aluminum salts in vaccines--US perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Mosquito distribution and entomological inoculation rates in three malaria-endemic areas in Gabon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Duration of humoral immunity to common viral and vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.09.011

1 reference

8 September 2017

1 reference